Effect of Randomization to a P2Y12 Inhibitor on the Number of Days Not Requiring Respiratory or Cardiovascular Organ Support and Survival Through 90 Days in Critically Ill Patients With COVID-19
death, respiratory or cardiovascular organ support, critically ill
REGRESSION, CRITICALLY ILL
(A) Data are shown as the number of days not requiring respiratory or cardiovascular organ support (eg, oxygen via high-flow nasal cannula ≥20 L/min, noninvasive or invasive mechanical ventilation, vasopressors, inotropes, or extracorporeal membrane oxygenation) as horizontally stacked proportions of patients in the 2 treatment groups, with the following possible outcomes: in-hospital death with or without organ support (dark red, the worst possible outcome, corresponding to a score of −1 on the ordinal scale), survival with organ support (red to blue gradient shading based on the number of days alive without organ support, corresponding to a score of 0-21 on the ordinal scale), and survival until hospital discharge without organ support (dark blue, the best possible outcome, corresponding to a score of 21 on the ordinal scale). (B) Kaplan-Meier curve showing survival through 90 days in critically ill patients. The 90-day survival in patients assigned to a P2Y12 inhibitor vs usual care was not significantly different in both a bayesian piecewise exponential model (adjusted hazard ratio, 0.99; 95% CI, 0.77-1.27; posterior probability of superiority, 53%) and a frequentist Cox proportional hazards regression model (adjusted hazard ratio, 0.96; 95% CI, 0.76-1.23; 